A physician scientist and senior executive with 25+ year biomedical research and biopharmaceutical R&D experience in oncology, form discovery, translational medicine to clinical development

Served as SVP and Head of Clinical Development at BeiGene, built BeiGene's clinical team and led the clinical development of 4 oncology assets from Phase I to pivotal trials including the first China-developed anti-PD-1 mAb

Led the research and development of over 10 oncology assets while serving as Oncology Medical Director at Covance (U.S.), Senior Principal Scientist in cancer translational medicine at Pfizer (U.S.) and Research Scientist in cancer genomics at Tularik/Amgen (U.S.)

Ph.D. from UT Southwestern Medical Center; postdoctoral fellowship at Harvard University; M.D. from Hubei Medical College

Over 23 years of experience in biopharmaceutical strategy and business development, and achieved more than 40 transactions across six continents totaling multiple billion dollars in transaction value

Leadership experience across all parts of the business development value chain from strategy, search and evaluation, negotiation and deal structuring to execution and alliance management

Business Alliance Lead for US, Latin America, Asia-Pacific, Japan, and China at Pfizer Essential Health

Extensive capital markets experience including fund raising and launching new companies

Over 20 years of experience in clinical and pharmaceutical industry, possessing extensive expertise in oncology and hematology

Previously served as Senior Medical Director at Covance Pharmaceutical Research and Development (Shanghai) Co., Ltd., leading numerous global and regional oncology and hematology projects

Formerly Medical Director at PAREXEL International in Singapore and China, overseeing medical and pharmacovigilance functions in the Asia-Pacific region and supporting drug development for global and Chinese pharmaceutical companies

Ph.D. in Microbiology from the National University of Singapore and a Medical Doctorate from Shandong Medical University

18 years of extensive experience in biopharmaceutical fields, specializing in the R&D, production, quality management, and project management of therapeutic antibody drugs

Successfully advanced multiple IND applications, technology transfers and business collaborations, leading various CMC development projects covering the entire life cycle, including upstream and downstream process development, analytical method development and validation, manufacturing scaling-up, clinical sample production and quality assurance management

Previously held positions at Shanghai Jiao Tong University and several renowned pharmaceutical companies, serving in roles including Senior Director of Process Development, Executive Director of R&D and Vice President of Quality Assurance

Ph.D. in Biochemistry and Molecular Biology from Shanghai Jiao Tong University and a Bachelor's degree in Biology from Inner Mongolia University

Over 10 years of experience in capital markets and corporate financial management. Prior to joining CStone in 2018, Nicky held roles in investment banking and hedge fund, accumulating extensive experience in both sell-side and buy-side in public and private markets

Previously worked at Deutsche Bank Hong Kong branch as an investment banker advising public and private companies in Asia on equity and debt financing, investments, and mergers and acquisitions, across a few industries from healthcare to internet and technology. Successfully completed initial public offerings (IPOs), multiple debt and equity programs of various structures and acquisitions, with cumulated transaction value exceeding $60 billion USD

Bachelor's degree in Finance and Economics from the Hong Kong University of Science and Technology, an MBA from Harvard Business School, and is a Chartered Financial Analyst

Over 20 years of experience in the life sciences industry

Previously served as the HR lead at Simcere-MSD (Shanghai) Pharmaceuticals Co., Ltd, where she was actively involved in the initial planning and establishment of a joint venture company, and she was responsible for HR management and orchestrating the foundational organizational framework during the nascent stages of the company's inception. Additionally, she held positions in several subsidiaries of Simcere Pharmaceutical (a company listed on the Hong Kong Stock Exchange, stock code: 2096), with her last position being the Head of Human Resources at Shanghai Simcere Pharmaceutical Co., Ltd

Master's degree in Applied Psychology from Nankai University and a Bachelor's degree in Business Administration from Inner Mongolia University of Finance and Economics